The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis

This publication has 32 references indexed in Scilit:

• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
  Journal of Crohn's and Colitis, 2012
• Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis
  Inflammatory Bowel Diseases, 2012
• Guidelines for the management of inflammatory bowel disease in adults
  Gut, 2011
• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
  American Journal of Gastroenterology, 2010
• Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
  Gastroenterology, 2009
• Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis
  Inflammatory Bowel Diseases, 2009
• Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
  Gut, 2008
• Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis
  Clinical Gastroenterology and Hepatology, 2007
• Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
  Gastroenterology, 2007
• Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis
  The American Journal of Medicine, 2003